Drug Trial Radar · NCT03711578
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Last checked: Nov 19, 2026Latest source record: Aug 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Nov 25, 2018
Primary completion
Jun 16, 2020
Study completion Oct 16, 2020
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),
Conditions
- Non Hodgkin Lymphoma
Interventions
Tenalisib,Drug
BID, Orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 7 months
- Complete Response RateTime frame: 7 months
- Progression Free Survival (PFS)Time frame: From date of first dose of tenalisib until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 months
- Duration of Response (DoR)Time frame: 7 months
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama
Colorado Blood Cancer Institute
Denver, Colorado
Florida cancer specialists & Research Institute
Florida City, Florida
Florida Cancer Specialist/ South
Fort Myers, Florida
Florida Cancer Specialists/North
St. Petersburg, Florida
HCA Midwest Health Kansas City
Kansas City, Missouri
Tennessee Oncology
Chattanooga, Tennessee
Tennessee Oncology
Nashville, Tennessee
Blacktown Hospital, Blacktown Cancer and Haematology Center
Blacktown, New South Wales, Australia
Brisbane Clinic for Lymphoma, Myeloma and Leukaemia,
Greenslopes, Queensland, Australia
John Flynn Private Hospital,
Tugun, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.